Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel antiphlogistic-analgesic agent

An anti-inflammatory analgesic and inhibitor technology, applied in the field of food and beverages and pharmaceutical compositions, can solve problems such as unclear mechanism of action, and achieve the effect of less side effects

Active Publication Date: 2010-03-24
MEIJI CO LTD
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its mechanism of action has not been clarified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel antiphlogistic-analgesic agent
  • Novel antiphlogistic-analgesic agent
  • Novel antiphlogistic-analgesic agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] [Example 1] (carrageenan foot edema inhibition test, effect on acute inflammation)

[0075] This example verified the inhibitory effect of whey protein isolate (WPI) and various proteins contained in WPI on carrageenan-induced foot swelling. In addition, WPI refers to a substance obtained by treating whey with microfiltration (MF), ultrafiltration (UF), cross-flow microfiltration (CFM), ion exchange, etc. to separate proteins and increase the protein concentration.

[0076] (method)

[0077] Oral administration of various test substances was performed using Wistar rats (male, 6-week-old, 6 rats per group, 5 groups) that had completed the acclimatization period of one week or more. As test substances, 1 g / kg [WPI group] of whey protein isolate (WPI, derived from bovine, manufactured by Davisco Foods International, Inc.), α-lactalbumin (α-LA, derived from Bovine, manufactured by Davisco Foods International, Inc.) 250 mg / kg (25w / w% of WPI) [aLA group], β-lactoglobulin (β...

Embodiment 2

[0080] [Example 2] (Adjuvant arthritis (treatment) model, effect on subacute inflammation (experimental chronic inflammation))

[0081]In this example, a rat adjuvant arthritis model was made as an animal model of rheumatoid arthritis to verify the therapeutic effect of various proteins contained in WPI on arthritis.

[0082] (method)

[0083] 0.1 mL of Freund's complete adjuvant was subcutaneously injected into the left paw of Wistar rats (male, 6 weeks old) whose acclimatization period was completed for more than one week, to induce adjuvant arthritis. The Freund's complete adjuvant used contained 8.5 mL of liquid paraffin, 1.5 mL of surfactant Span 80, and 7.5 mg of inactivated human tuberculosis H37Rv in 10 mL. Fourteen days after the start of the adjuvant administration, rats with sufficient arthritis were selected and divided into groups based on the foot volume of the left foot (6 rats in 1 group and 5 groups).

[0084] Each of the test substances (α-lactalbumin [aLA ...

Embodiment 3

[0088] [Example 3] (adjuvant arthritis (pain) model, effect on chronic pain)

[0089] Wistar rats (male, 6 weeks old) who had completed the acclimatization period for more than one week were subcutaneously injected with 0.1 mL of the same Freund's complete adjuvant as in Example 2 to induce adjuvant arthritis. Sixteen days after the start of the adjuvant administration, rats with sufficient arthritis were selected and divided into groups based on the volume of the left paw (6 rats in 1 group and 5 groups).

[0090] Each of the test substances (α-lactalbumin [aLA group], β-lactoglobulin [bLG group], lactoferrin [LF group]) dissolved in physiological saline at 300 mg / kg will be used as an anti-inflammatory analgesic Diclofenac [positive control group] was orally administered at a dosage of 50 mg / kg in a volume of 4 ml / kg. One hour after the administration of the test substance, whether or not there was a vocalization response to the stimulation of bending and stretching of the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The object is to provide a novel antiphlogistic-analgesic agent which is highly safe and can be administered over a long period. A study is made on the antiphlogistic-analgesic effect of a-lactalbumin which is one of natural substances contained in foods, and it is found that alpha-lactalbumin exhibits a cyclooxygenase-2(COX-2) inhibition activity and a phospholipase-A2 inhibition activity in vitro. In the in vivo test using a carrageenin food edema model, an adjuvant arthritis model and an acetic acid writhing test, it is also found that alpha-lactalbumin exhibits an anti-inflammatory effect. Further, it is also found that alpha-lactalbumin inhibits COX-2 more selectively compared to COX-1. Therefore, alpha-lactalbumin can be used as an antiphlogistic-analgesic agent having few adverse side effects.

Description

technical field [0001] The present invention relates to a food and drink and a pharmaceutical composition containing α-lactalbumin and having anti-inflammatory and analgesic effects. Background technique [0002] Today, as daily prescription drugs for anti-inflammatory and analgesic, there are dozens of synthetic compounds such as aspirin, indomethacin, ibuprofen, diclofenac, etc. Corticosteroids, etc. [0003] Aspirin inhibits the activity of prostaglandin (PG) synthetase, or "cyclooxygenase (COX)". Due to the reduction of COX activity, PG is reduced, thereby inhibiting the activity of pain-inducing substances (bradykinin), thereby exerting the analgesic effect of aspirin. Drugs that act on COX in the same way as aspirin to exert anti-inflammatory and analgesic effects are called "non-steroidal anti-inflammatory drugs (NSAIDs)" in order to distinguish them from steroidal agents with different mechanisms of action. ". [0004] NSAIDs have the disadvantage of easily causi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P19/02A23L1/30A61P29/00A23L2/52A61P43/00
CPCA23V2002/00A61K38/38A23L1/3056A23L33/19A61P15/00A61P19/02A61P29/00A61P43/00A23V2200/324A23V2200/02A23V2250/54242
Inventor 山口真内田胜幸
Owner MEIJI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com